Latest Biotech News

enGene’s shares plunged after updated Phase II LEGEND trial data for its nonviral gene therapy candidate, detalimogene (formerly EG-70), in high-risk BCG-unresponsive nonmuscle invasive bladder...

Blackstone Life Sciences committed $250 million to Anagram Therapeutics, backing the company’s oral enzyme replacement therapy program for patients with exocrine pancreatic insufficiency. The...

Windward Bio secured $165 million to advance long-acting antibody programs across asthma and COPD, with additional development planned for respiratory and dermatological indications. The financing...

A new post-hoc analysis set for presentation at ECO 2026 will examine the efficacy and safety of orforglipron in adults aged 65 and older, stratified by obesity with and without type 2 diabetes....

Researchers at the University of Rochester reported transferring a longevity-related gene from naked mole rats into mice, with the engineered animals living longer and showing improved health...

Investigators evaluated bioequivalence of pramipexole dihydrochloride extended-release tablets in Chinese healthy volunteers under fasting versus fed conditions. The pharmacokinetic comparison...

A new analysis spotlights operational bottlenecks in the logistics of next-generation cell and gene therapies, where delivery windows and product sensitivity can be measured in minutes. The report...

A large group of National Academy of Sciences experts denounced the White House’s dismissal of the National Science Board, warning it undermines the country’s ability to engage in basic and...

Next-generation cell and gene therapies are driving a logistics overhaul because supply chains must protect living, patient-specific products through extremely tight stability windows. The...

Biopharma expansion is turning into a location-led competition as capacity constraints outpace timelines for new GMP facility builds. The industry is prioritizing ‘ready-now’ sites—areas with...

JACIE completed the first-ever inspection under its third edition Immune Effector Cells (IEC) Standards at Guy’s and St Thomas’ NHS Foundation Trust in Barcelona as the field expands certification...

Windward Bio raised $165 million to fund clinical trials targeting respiratory disorders, expanding its portfolio in asthma, COPD, and additional potential indications. The funding supports at...

Blackstone Life Sciences committed $250 million to Anagram Therapeutics, backing development of an oral enzyme replacement therapy for patients with exocrine pancreatic insufficiency. The deal...

enGene’s stock plunged after updated Phase II LEGEND trial data for its nonviral gene therapy detalimogene voraplasmid in high-risk, BCG-unresponsive nonmuscle invasive bladder cancer. Updated...

Researchers identified pharmacological markers that could refine oral PrEP dosing for men who have sex with men (MSM), according to work published in Nature Communications. The study focuses on...

A new post-hoc analysis set for presentation at the European Congress on Obesity (ECO 2026) will evaluate orforglipron, an oral GLP-1 receptor agonist, in adults aged 65 and older with obesity....

10x Genomics launched Atera, a new in situ spatial biology platform designed to deliver whole-transcriptome spatial analysis with single-cell sensitivity at scale. The company said Atera can...

Medicare spending on newly approved Alzheimer’s drugs Leqembi and Kisunla is tracking far below earlier projections, according to a CMS spokesperson cited by STAT+. Uptake has been so muted that...

enGene reported updated Phase II LEGEND trial data for its nonviral gene therapy detalimogene voraplasmid in high-risk, BCG-unresponsive nonmuscle invasive bladder cancer with carcinoma in situ...

Windward Bio secured $165M in financing to support clinical testing of long-acting antibodies targeting respiratory disorders. The raise is intended to advance a lead program in asthma and COPD,...